$XBI $77.06 | +1.09%
Table of Contents:
Pipeline Updates
#IKNA +29.4% (6/22) Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma. source
#AVTE +21.8%
#OMGA +21.3% (6/23) Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer. source
#BCAB +18.3%
#ANEB +18.0% (6/23) Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022. source
#WVE +17.5%
#CMRX +13.2% Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada. source
#NTLA +5.2% Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose. source
#HZNP +2.7% New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD). source
#EBS +1.3% Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate. source
#GILD +0.8% Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV. source
#CYTK -0.5% CYTOKINETICS ANNOUNCES DATE FOR FDA ADVISORY COMMITTEE MEETING TO REVIEW NEW DRUG APPLICATION FOR OMECAMTIV MECARBIL. source
#PLRX -1.5% Pliant Therapeutics Announces Presentations at the International Liver Congressâ„¢ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial. source
#ADVM -1.9% Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD. source
#MIRM -9.0% Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting. source
#MIRM -9.0% Mirum Pharmaceuticals Presents New Data at The International Liver Congressâ„¢ of the European Association for the Study of the Liver (EASL). source
#IMRX -11.7%
#CUE -11.8%
#VALN -13.3% Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001. source
#LBPH -19.8%
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
Posted by DV/FS